濮阳东方医院看妇科技术专业濮阳东方看男科评价好收费低,濮阳东方评价好吗,濮阳东方医院治阳痿口碑非常好,濮阳东方男科口碑比较好,濮阳东方看男科评价好很不错,濮阳东方医院治早泄技术很专业,濮阳东方看男科病很便宜

WASHINGTON, May 1 (Xinhua) -- The launch of U.S. space shuttle Endeavour on its final voyage will be no earlier than May 8, after technical problems uncovered last week proved more complex than originally thought, the U.S. National Aeronautics and Space Administration (NASA) announced Sunday.NASA tried to launch Endeavour on Friday on its 25th and final flight to deliver the 2-billion-dollar Alpha Magnetic Spectrometer (AMS) particle detector to the International Space Station. AMS, a particle physics detector, is designed to search for various types of unusual matter by measuring cosmic rays. Its experiments are designed to help researchers study the formation of the universe and search for evidence of dark matter, strange matter and antimatter.The space shuttle Endeavour sits on launch pad 39A as work continues on the shuttle's auxilliary power unit at the Kennedy Space Center in Cape Canaveral, Florida May 1, 2011.However, the launch was called off after engineers detected a failure in one of two heater circuits associated with Auxiliary Power Unit (APU) 1. Heaters are required to keep the APUs' hydrazine from freezing on orbit.NASA hoped Endeavour would lift off on Monday. But further trouble-shooting indicated the glitch was more complicated than officials hoped initially.The failure appears to be a power problem within the aft load control assembly-2, a box of switches controlling power feeds."That basically means the power is not getting out to the heaters that weren't working on launch day," said Space Shuttle Program Launch Integration Manager Mike Moses.

SAN FRANCISCO, March 8 (Xinhua) -- Google on Tuesday released a new stable version of its Chrome web browser, which the company said is speedier, simpler and safer."With today's stable release, even your most complex web apps will run more quickly and responsively in the browser," Tim Steele, a Google software engineer, said in a blog post announcing the release.The new version of Chrome features a simpler settings page that opens in a tab rather than a dialog box, and contains a search box showing users the settings they are looking for while they type.Users can also synchronize passwords in the browser across their computers, and will be able to encrypt those passwords for extra security.Google said that the latest Chrome browser provides additional layer of protection against malicious web pages, with the extended application of sandboxing technology.The browser can be downloaded for free, and current Chrome users will be automatically updated to the new version soon, Google said.

VIENNA, April 12 (Xinhua) -- A protein group has been identified as an "allergy multiplier" that causes food allergy, a symptom that could also accompany other allergies and produce serious consequences, Austrian researchers said Tuesday.The so-called non-specific lipid transfer proteins (nsLTP) are believed to be the causes of food allergy, a research team from the Medical University of Vienna said in a new report.These plant allergens are found not only in many fruits and vegetables, but also in cereals and some types of pollen. Due to their compact structures, they are not degraded in the gastrointestinal tract and can trigger immune reactions that cause severe allergic symptoms, said the report.The researchers believe that with nsLTP identified as an " allergy multiplier," diagnostic and treatment procedures could be adapted and improved.

TIANJIN, April 16 (Xinhua) -- As China tries to establish a universal medicare umbrella, its first move to offer treatment to all the hemophilia patients in the country is to know their population and where they are.China's national hemophilia information management center registered 7,980 cases nationwide since its establishment last year in a bid to provide reference for making national treatment policies and medicine production quota, said the center officials Saturday.Yang Renchi with the center and the Chinese Academy of Medical Sciences, said that the patient information database will help the government make hemophilia-related medical and social welfare policies, optimize resources and guide the manufacturing of drugs such as coagulation factor VIII.The information center, created by the Ministry of Health, is located in the Blood Diseases Hospital of the Chinese Academy of Medical Sciences in the port city Tianjin in north China.Hemophilia is a rare genetic bleeding disorder that prevents the blood from clotting properly, resulting in easy bruising and prolonged bleeding from trauma. Lack of treatment can lead to permanent disabilities or even death.China is estimated to have roughly 100,000 hemophilia patients."Be inspired; get involved in Treatment for All" is the theme for the 22nd World Hemophilia Day, which falls on Sunday, April 17."A necessary precondition for 'Treatment for All' is to know the clinical information and location of each case," said Yang, "and this is exactly what the information system does."In addition, China plans to establish hospital-based provincial hemophilia management centers within five years across the country to register and monitor patients and standardize disease diagnosis and treatment under the information system.SHORTAGE OF DRUGSBlood-derived coagulation factor VIII and recombinant coagulation factor VIII are two effective drugs which are vital for hemophiliacs. However, the drugs are expensive and produced in limited quantities, a difficulty which hundreds of thousands of hemophiliacs in China have to confront.According to Yang, the minimum dose of coagulation factor VIII for prevention of bleeding episodes is two international units (IU) per kg of weight a day. A 50-kg hemophilia patient needs at least 36,500 IU of factor VIII every year to prevent bleeding."Each IU of blood-derived coagulation factor VIII costs about 3 yuan(0.46 U.S. dollars) and the annual cost is almost 120,000 yuan. The recombinant one is almost twice the price," said Yang.Only four drug firms are qualified to manufacture blood-derived coagulation factor VIII in China. The national output in 2010 was 400,000 vials (200 IU per vial) which means 80 million IU for the entire country.Wu Runhui, a hematology specialist with the Beijing Children's Hospital, said that the minimum dose is only for the prevention of bleeding episodes which are required to keep the patient alive. For the hemophiliac to live a regular lifestyle, 3,000 IU per kilo a year is needed, which would cost half a million yuan a year."Even in the most developed countries, a hemophiliac cannot survive without supportive medical policies and social welfare system," said Wu.

JERUSALEM, March 31 (Xinhua) -- Two researchers at the Hebrew University (HU) of Jerusalem have been honored with a prestigious award for their study of the connection between several inflammatory diseases, cancer and bacteria.Medical faculty members, Dr. Eli Pilarsky and Prof. Sigal Ben- Yehuda, won this year's Sir Zelman Cowen Universities Fund prize that recognizes significant achievement in the field of medicine.The prize committee noted the impressive contributions of Pilarsky and Ben-Yehuda in understanding complex diseases like cancer and antibiotic-resistant infections, and, in a first, decided to award the two scientists this year.Pilarsky told Xinhua that his research deals with the connection between chronic inflammatory diseases like hepatitis, and the development of cancer cells."The relevance of this discovery is that we were able to establish the link between the molecules secreted with such inflammations and the proliferation of cancer cells," Pilarsky explained, noting that "we discovered that the inflammation favors the cancer cells' growth, and now we are trying to find a way to manipulate these molecules to stop the cancer cells from appearing. ""The importance of these findings lies in the fact that 20 percent of the world's cancer cases are attributed to inflammation processes," Pilarsky pointed out.